RxDoctor Payments Data

Michael Heublum, MD

Neurology · Palisades Park, NJNPI 1336168954

Payments from drug & device makers

$26,237in general payments, 2019–2025

Across 842 payments — averaging $31.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Neurocrine Biosciences, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Lilly USA, LLC$1K
  • Biogen$1K
  • Amgen$1K
  • plus $15K from 47 others

What the payments were for

  • Speaking & faculty fees$490%
  • Food & beverage$26,02099%
  • Education$1681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,237 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$94,066
Medicare patients
301
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate37$179,967
VumerityDiroximel Fumarate11$95,965
NourianzIstradefylline14$27,060
NuedextaDextromethorphan Hbr/Quinidine11$17,031
OngentysOpicapone24$16,283
Dalfampridine ErDalfampridine17$15,718
QuviviqDaridorexant Hcl24$11,624
AdlarityDonepezil Hcl14$6,300
RytaryCarbidopa/Levodopa12$4,045
Sumatriptan Succinate39$3,852
Carbidopa-LevodopaCarbidopa/Levodopa96$2,596
Memantine Hcl111$2,575
Donepezil Hcl249$2,009
Gabapentin90$1,782
AmantadineAmantadine Hcl14$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$283$179,96737 claims
BiogenVumerity$1,221$95,96511 claims
Kyowa Kirin, Inc.Nourianz$567$27,06014 claims
Avanir Pharmaceuticals, Inc.Nuedexta$322$17,03111 claims
Neurocrine Biosciences, Inc.Ongentys$1,615$16,28324 claims
Idorsia Pharmaceuticals US IncQuviviq$71$11,62424 claims
Corium, LLCAdlarity$409$6,30014 claims
Amneal Pharmaceuticals LLCRytary$1,109$4,04512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Palisades Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →